Acquired genetic alterations in the EGFR, KRAS, NRAS, BRAF, ROS1 and ALK oncogenes are the most common mutations in NSCLC and certain mutations are associated with drug sensitivity or resistance [6, 7]. This evidence concerns the gene NRAS and non-small cell lung carcinoma.